发布求助
文献互助 智能选刊 最新文献

Skin therapy letter最新文献

筛选
英文 中文
An Anti-Wrinkle Diet: Nutritional Strategies to Combat Oxidation, Inflammation and Glycation 抗皱饮食:抗氧化、炎症和糖基化的营养策略
Skin therapy letter Pub Date : 2020-03-01
Rajani Katta, Ariadna Sanchez, Evelyne Tantry
{"title":"An Anti-Wrinkle Diet: Nutritional Strategies to Combat Oxidation, Inflammation and Glycation","authors":"Rajani Katta,&nbsp;Ariadna Sanchez,&nbsp;Evelyne Tantry","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>There is growing awareness of the complex link between nutrition and skin. In the last few decades, our understanding of this link has grown significantly with research findings from multiple laboratory, animal, and human studies. From the impact of diet on clinical features of aging skin, to documentation of the biochemical and histologic changes that occur, our understanding of this link continues to expand and evolve. In this paper, we review the research on the impact of diet on skin aging. A number of long-term observational population studies have documented that healthier diets are linked to fewer signs of skin aging. Animal and laboratory studies have elucidated the biochemical processes that play a large role in the development of these clinical findings. A number of studies have also reported on the role of specific dietary compounds in impacting these processes, whether by combating or potentiating these forces. This body of research serves as guidance in recommending nutritional strategies that can combat the skin aging forces of oxidation, inflammation, and glycation.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"25 2","pages":"3-7"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37757847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Topical Retinoid for Acne: Trifarotene 50 μg/g Cream 一种用于痤疮的新型局部类维生素A:三胡萝卜素50 μg/g乳膏
Skin therapy letter Pub Date : 2020-03-01
Jerry Tan, Maegan Miklas
{"title":"A Novel Topical Retinoid for Acne: Trifarotene 50 μg/g Cream","authors":"Jerry Tan,&nbsp;Maegan Miklas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Trifarotene 50 μg/g cream is a fourth generation topical retinoid with retinoic acid receptor gamma selectivity. It was recently approved by the US FDA and Health Canada for the topical treatment of facial and truncal acne for those aged 9 and older based on two identically designed phase 3 trials demonstrating superiority in lesion count reduction and global acne improvement compared to vehicle. These studies and a 1 year study also demonstrated safety and tolerability with cutaneous adverse events developing in an anticipated timeframe (1 week) for the face. These were of lesser degree and tended to develop later at the trunk. Future studies will be required to evaluate the comparative efficacy of trifarotene 50 μg/g cream against other treatments for acne.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"25 2","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37757845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Ichthyosis: A Brief Review 鱼鳞病的治疗:简要回顾
Skin therapy letter Pub Date : 2020-01-01
Allison L Limmer, Crystal E Nwannunu, Ravi R Patel, Uyen N Mui, Stephen K Tyring
{"title":"Management of Ichthyosis: A Brief Review","authors":"Allison L Limmer,&nbsp;Crystal E Nwannunu,&nbsp;Ravi R Patel,&nbsp;Uyen N Mui,&nbsp;Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The ichthyoses, also termed the disorders of keratinization, are a heterogenous group of skin diseases in which a distinctive horny layer arises secondary to excessive transepidermal water loss. Although occasionally acquired, the majority of ichthyoses are inherited and can be pinpointed to characteristic genetic mutations. Management depends on disease severity and includes topical agents and lifestyle modifications with or without oral retinoids. Genetic counseling is also an important consideration. This review aims to highlight advances in our understanding of disease pathogenesis as well as the holistic approach necessary to adequately manage ichthyosis patients.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"25 1","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37612369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydrogen Peroxide Topical Solution, 40% (w/w) for the Treatment of Seborrheic Keratoses: A Review 过氧化氢局部溶液，40% (w/w)用于治疗脂溢性角化病:综述
Skin therapy letter Pub Date : 2020-01-01
Emily C Murphy, Adam J Friedman
{"title":"Hydrogen Peroxide Topical Solution, 40% (w/w) for the Treatment of Seborrheic Keratoses: A Review","authors":"Emily C Murphy,&nbsp;Adam J Friedman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>HP40 (Eskata™) is a stabilized, topical solution of 40% hydrogen peroxide (H2O2) packaged in an applicator pen that is\u0000US FDA-approved to treat seborrheic keratoses (SKs). By harnessing the oxidative capabilities of H2O2 , 1-2 treatments with HP40 produced a higher rate of clearance of four SKs per patient compared to vehicle in two phase 3 trials. The clearance rate was higher for the face than the trunk and extremities. Similarly, the risks of pigmentary changes and scarring from HP40 were lower for the face than other locations. Further, based on an ex vivo study, HP40 may be less cytotoxic to melanocytes than cryotherapy, but clinical trials comparing these therapies are needed. Limitations of HP40 are its low efficacy and requirement of multiple treatments, which can result in elevated costs. The application can also be time-consuming, though extenders or even staff members can apply it. Therefore, HP40 may be better reserved for the treatment of facial SKs.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"25 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37613907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review 局部地塞米林软膏治疗单纯大疱性表皮松解症的研究进展
Skin therapy letter Pub Date : 2019-05-01
Allison L Limmer, Crystal E Nwannunu, Radhika Shah, Kendall Coleman, Ravi R Patel, Uyen Ngoc Mui, Stephen K Tyring
{"title":"Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review","authors":"Allison L Limmer,&nbsp;Crystal E Nwannunu,&nbsp;Radhika Shah,&nbsp;Kendall Coleman,&nbsp;Ravi R Patel,&nbsp;Uyen Ngoc Mui,&nbsp;Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Epidermolysis bullosa (EB) is a group of rare mucocutaneous fragility disorders often presenting in infancy and early childhood with painful blistering of the skin and mucous membranes. The severity of EB blister burden varies by disease subtype. Studies have shown that patients with generalized severe epidermolysis bullosa simplex (EBS), a variant characterized by extreme fragility, develop blisters in the setting of overproduced, mutated K14 protein, a component of the intermediate filament integral in keratinocyte stability, and constitutive activation of interleukin (IL)-1 , a pro-inflammatory cytokine that promotes the hyperproliferation of keratinocytes. Diacerein, a rhein prodrug and anthraquinone, has been shown to reduce expression of K14 and inhibit IL-1 converting enzyme. In clinical trials, topical 1% diacerein was shown to be an effective and safe, non-invasive treatment for patients suffering from EBS. This review examines the clinical trials of topical diacerein and its role in EBS. Diacerein ointment was granted US FDA Rare Pediatric Disease designation in May 2018 and Fast Track development designation in August 2018.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"24 3","pages":"7-9"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37249243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on the Management of Vitiligo 管理白癜风的最新情况
Skin therapy letter Pub Date : 2019-05-01
Amanda F Nahhas, Taylor L Braunberger, Iltefat H Hamzavi
{"title":"Update on the Management of Vitiligo","authors":"Amanda F Nahhas,&nbsp;Taylor L Braunberger,&nbsp;Iltefat H Hamzavi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Vitiligo is an acquired, autoimmune disease characterized by depigmented macules and patches on the skin, which occur secondary to melanocyte destruction. Available therapeutic options are broadly divided into medical, surgical and phototherapy, though treatment of vitiligo can be challenging. Early diagnosis and management can maximize treatment efficacy. The purpose of this discussion is to review updates in the management of vitiligo, including existing and emerging therapies.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"24 3","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37249241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis Crisaborole 2%软膏(Eucrisa)治疗特应性皮炎
Skin therapy letter Pub Date : 2019-03-01
Taylor Evart Woo, Paul Kuzel
{"title":"Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis","authors":"Taylor Evart Woo,&nbsp;Paul Kuzel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis is a common cutaneous disease with significant morbidity affecting children and adults. The mainstay of atopic dermatitis therapy has typically included emollients, topical corticosteroids, and topical calcineurin inhibitors. Among the newer advances recently introduced is crisaborole (Eucrisa™), a phosphodiesterase type-4 inhibitor (PDE-4) for the treatment of mild moderate atopic dermatitis. Evidence from phase 3 trials demonstrates crisaborole as an efficacious topical agent with a favorable safety profile and limited systemic exposure. While the efficacy of crisaborole compared to existing therapies remains unknown, crisaborole is a promising candidate in the treatment of atopic dermatitis.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"24 2","pages":"4-6"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37302742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis Tosylate glycopyronium治疗多汗症
Skin therapy letter Pub Date : 2019-03-01
Crystal E Nwannunu, Allison L Limmer, Kendall Coleman, Radhika Shah, Ravi R Patel, Uyen Ngoc Mui, Stephen K Tyring
{"title":"Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis","authors":"Crystal E Nwannunu,&nbsp;Allison L Limmer,&nbsp;Kendall Coleman,&nbsp;Radhika Shah,&nbsp;Ravi R Patel,&nbsp;Uyen Ngoc Mui,&nbsp;Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hyperhidrosis is a condition characterized by excessive sweat production beyond which is physiologically necessary for thermal regulation. Affecting over 4.8% of the United States population, studies have shown that severe primary hyperhidrosis interferes with daily activities and can be considered intolerable, negatively impacting a patient’s quality of life. Glycopyrronium tosylate is a topical anticholinergic agent that reduces sweat production by blocking the activation of acetylcholine receptors in peripheral sweat glands. In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown to be an effective, safe and non-invasive treatment for patients suffering from primary hyperhidrosis. This review examines the clinical trials of topical glycopyrronium tosylate and its role in primary hyperhidrosis. Glycopyrronium tosylate was recently US FDA-approved (as of June 2018) to manage patients with primary axillary hyperhidrosis.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"24 2","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37302741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on Immunotherapeutics in the Management of Metastatic Melanoma 转移性黑色素瘤的免疫治疗进展
Skin therapy letter Pub Date : 2019-01-01
David Bulir, Steven Liang, Maureen O’Malley, Elaine McWhirter
{"title":"Update on Immunotherapeutics in the Management of Metastatic Melanoma","authors":"David Bulir,&nbsp;Steven Liang,&nbsp;Maureen O’Malley,&nbsp;Elaine McWhirter","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Today, a number of treatment options are now available for metastatic melanoma. Within the last decade, the development of novel immunotherapies for cancer has significantly altered the course of the disease in patients with melanoma. With more patients receiving these potentially life-saving treatments, not only have we learned more about the interplay between the immune system and melanoma, but more importantly, which treatment options are most appropriate given the clinical picture.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"24 1","pages":"8-11"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37009290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Treatment of Primary Focal Hyperhidrosis 原发性局灶性多汗症的治疗
Skin therapy letter Pub Date : 2019-01-01
Todd Wechter, Steven R Feldman, Sarah L Taylor
{"title":"The Treatment of Primary Focal Hyperhidrosis","authors":"Todd Wechter,&nbsp;Steven R Feldman,&nbsp;Sarah L Taylor","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Primary focal hyperhidrosis is a relatively common disease that has a significant impact on afflicted patient’s quality of life. The pathogenesis of the disease is thought to stem from increased cholinergic activity on eccrine sweat glands. Topical aluminum chloride based antiperspirants are good first-line agents for all affected body sites. Anticholinergic agents are emerging as effective topical alternatives. Iontophoresis passes an electrical current through the skin and is an excellent treatment option for palmoplantar disease. Botulinum toxin type A injections remain a mainstay second-line treatment. Local procedural advances including microwave thermolysis, laser therapy and focused ultrasound are emerging as safe and effective alternatives for refractory disease. Oral anticholinergics are generally well tolerated and can also be used for intractable disease. Last-line interventions include local surgical options and sympathectomy, though some patients may prefer permanent treatment. Further investigation of novel treatments as well as ways to optimize existing therapeutic options are needed.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"24 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37009797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信